Victory Capital Management’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-15,908
| Closed | -$1.15M | – | 2481 |
|
|
2025
Q4 | $1.15M | Sell |
15,908
-275,139
| -95% | -$17.8M | ﹤0.01% | 1766 |
|
|
2025
Q3 | $12.7M | Buy |
291,047
+243,579
| +513% | +$9.85M | 0.01% | 1018 |
|
|
2025
Q2 | $1.35M | Buy |
47,468
+5,765
| +14% | +$172K | ﹤0.01% | 1713 |
|
|
2025
Q1 | $1.23M | Buy |
41,703
+3,395
| +9% | +$106K | ﹤0.01% | 1705 |
|
|
2024
Q4 | $1.11M | Buy |
38,308
+5,124
| +15% | +$214K | ﹤0.01% | 1758 |
|
|
2024
Q3 | $1.52M | Buy |
33,184
+11,367
| +52% | +$493K | ﹤0.01% | 1588 |
|
|
2024
Q2 | $891K | Buy |
21,817
+12,497
| +134% | +$359K | ﹤0.01% | 1760 |
|
|
2024
Q1 | $238K | Buy |
+9,320
| New | +$146K | ﹤0.01% | 2178 |
|
|
2022
Q4 | – | Sell |
-19,842
| Closed | -$324K | – | 2690 |
|
|
2022
Q3 | $324K | Buy |
19,842
+362
| +2% | +$6.92K | ﹤0.01% | 2221 |
|
|
2022
Q2 | $283K | Buy |
19,480
+387
| +2% | +$5.76K | ﹤0.01% | 2256 |
|
|
2022
Q1 | $273K | Sell |
19,093
-267
| -1% | -$4.54K | ﹤0.01% | 2326 |
|
|
2021
Q4 | $460K | Sell |
19,360
-3,153
| -14% | -$75.3K | ﹤0.01% | 2194 |
|
|
2021
Q3 | $554K | Sell |
22,513
-1,034,799
| -98% | -$22.5M | ﹤0.01% | 2122 |
|
|
2021
Q2 | $26.1M | Buy |
1,057,312
+35,256
| +3% | +$820K | 0.03% | 802 |
|
|
2021
Q1 | $22.3M | Buy |
1,022,056
+168,764
| +20% | +$4.13M | 0.02% | 870 |
|
|
2020
Q4 | $21.8M | Buy |
853,292
+49,925
| +6% | +$1.46M | 0.02% | 848 |
|
|
2020
Q3 | $22.6M | Sell |
803,367
-87,413
| -10% | -$2.53M | 0.03% | 737 |
|
|
2020
Q2 | $25.2M | Buy |
+890,780
| New | +$25.7M | 0.03% | 689 |
|
Other funds holding RNAM
Victory Capital Management's RNAM Position: Q1 2026 in Review
Victory Capital Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 15,908 shares — an estimated $1.15M sold.
Victory Capital Management first reported a position in RNAM in Q2 2020 and held it in 18 quarters. The position peaked at $26.1M in Q2 2021. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Victory Capital Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Victory Capital Management sold 15,908 Avidity Biosciences shares in Q1 2026, an estimated $1.15M.
- Victory Capital Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 18 quarters.
- Victory Capital Management's Avidity Biosciences position peaked at $26.1M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.